Cardiovascular risk of selective cyclooxygenase-2 inhibitors.

abstract：BACKGROUND:Allogeneic cardiosphere-derived cells (CDCs) exert cardioprotective effects when administered intracoronarily after reperfusion in animal models of acute myocardial infarction (AMI). The "no-reflow" phenomenon develops rapidly post-reperfusion and may undermine the efficacy of cell therapy, due to poor cell ...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Sousonis V,Sfakianaki T,Ntalianis A,Nanas I,Kontogiannis C,Aravantinos D,Kapelios C,Katsaros L,Nana M,Sampaziotis D,Sanoudou D,Papalois A,Malliaras K

更新日期：2021-01-01 00:00:00

abstract：:Although COVID-19 is viewed primarily as a respiratory disease, cardiovascular risk factors and disease are prevalent among infected patients and are associated with worse outcomes. In addition, among multiple extra-pulmonary manifestations, there has been an increasing recognition of specific cardiovascular complicat...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Kelham M,Choudry FA,Hamshere S,Beirne AM,Rathod KS,Baumbach A,Ahluwalia A,Mathur A,Jones DA

更新日期：2020-12-17 00:00:00

abstract：:Lidocaine-sensitive, repetitive atrial tachycardia is an uncommon arrhythmia. The electrophysiologic substrate is still unknown, and the pharmacologic responses have not been fully explored. The aim of this study was to investigate the effects of intravenous adenosine and verapamil in patients with lidocaine-sensitive...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Chiale PA,Faivelis L,Garro HA,Fernández PA,Herrera Paz JJ,Elizari MV

更新日期：2012-06-01 00:00:00

abstract：:The effects of nitric oxide (NO) and noradrenergic activation in the posterior hypothalamus on arterial pressure tolerance induced by subcutaneous injection of nitroglycerin (NTG) was investigated in anesthetized Sprague-Dawley rats. Intravenous injections of NTG (3, 10, and 30 microg/kg) and sodium nitroprusside (1, ...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Guettler DL,Ma SX

更新日期：2008-06-01 00:00:00

abstract：:We present two patients who were diagnosed with symptomatic sinus node dysfunction in the setting of hypercalcemia secondary to hyperparathyroidism. An extensive review of the literature has not revealed previous reports of this pathologic process. ...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Shah AP,Lopez A,Wachsner RY,Meymandi SK,El-Bialy AK,Ichiuji AM

更新日期：2004-06-01 00:00:00

abstract：:The National Heart, Lung, and Blood Institute convened a Workshop on September 20-21, 2010, "New Horizons in Cardioprotection," to identify future research directions for cardioprotection against ischemia and reperfusion injury. Since the early 1970s, there has been evidence that the size of a myocardial infarction co...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Kloner RA,Schwartz Longacre L

更新日期：2011-09-01 00:00:00

abstract：BACKGROUND:CVT-510, N-(3(R)-tetrahydrofuranyl)-6-aminopurine riboside, is a selective A(1)-adenosine receptor agonist with potential potent antiarrhythmic effects in tachycardias involving the atrioventricular (AV) node. This study, the first in humans, was designed to determine the effects of CVT-510 on AV nodal condu...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Lerman BB,Ellenbogen KA,Kadish A,Platia E,Stein KM,Markowitz SM,Mittal S,Slotwiner DJ,Scheiner M,Iwai S,Belardinelli L,Jerling M,Shreeniwas R,Wolff AA

更新日期：2001-07-01 00:00:00

abstract：:A large body of evidence indicates that a persistently high heart rate is associated with a significant risk for higher mortality and sudden death in individuals with a variety cardiovascular disorders, as well as in the general population. Heart rates elevated beyond a certain threshold have been found to be a risk f...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Singh N

更新日期：2002-04-01 00:00:00

abstract：:Neuropeptide Y is released together with norepinephrine from sympathetic nerve terminals during conditions of increased sympathetic activity. Neuropeptide Y is known to inhibit vagal activity, and accordingly, it might increase the risk for ventricular fibrillation during myocardial ischemia-reperfusion, with concomit...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Ilebekk A,Eriksen M,Sevre K,Aspelin T,Björkman JA,Lyberg T,Nordlander M

更新日期：2006-09-01 00:00:00

abstract：:The existing clinical studies on remote ischemic preconditioning in patients undergoing cardiovascular surgery are critically reviewed, with a focus on infarct size reduction and clinical outcome as end points. Confounders, notably the use of propofol anesthesia are identified. The need for better designed trials with...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Heusch G

更新日期：2017-07-01 00:00:00

abstract：INTRODUCTION:Angiotensin converting enzyme inhibitors (ACEIs) are widely prescribed medications. A recent British study reported a 14% increased risk of lung cancer with ACEI versus angiotensin receptor blocker (ARB) prescriptions, and risk increased with longer use. We sought to validate this observation. METHODS:We ...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Anderson JL,Knowlton KU,Muhlestein JB,Bair TL,Le VT,Horne BD

更新日期：2021-01-29 00:00:00

abstract：BACKGROUND:Published data indicated that combination use of clopidogrel and proton pump inhibitors (PPIs) may increase the incidence of major adverse cardiovascular events (MACEs). This has been a highly controversial topic for years. DESIGN:The present study was performed to evaluate whether combination therapy of cl...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Niu Q,Wang Z,Zhang Y,Wang J,Zhang P,Wang C,Yin X,Hou Y

更新日期：2017-03-01 00:00:00

abstract：OBJECTIVE:Acute lung injury is a common complication after cardiopulmonary bypass (CPB). Oxidative damage greatly impacts CPB-induced lung ischemic pathogenesis and may represent a target for treatment. We aimed to investigate whether curcumin upregulates heme oxygenase 1 (HO-1) expression and ameliorates lung injury i...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Liu K,Chen HL,Huang H,Jing H,Dong GH,Wu HW,You QS

更新日期：2012-12-01 00:00:00

abstract：:Dofetilide is a class III antiarrhythmic agent approved by the Food and Drug Administration for the conversion of atrial fibrillation and atrial flutter and maintenance of sinus rhythm in symptomatic patients with persistent arrhythmia. Drug trials showed neutral mortality in post-myocardial infarction patients and th...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Wolbrette DL,Hussain S,Maraj I,Naccarelli GV

更新日期：2019-01-01 00:00:00

abstract：:Congestive heart failure is a chronic and debilitating disease responsible for high cardiac morbidity and mortality in the world and is associated with more than 290 000 deaths in the United States each year. Recent advances in heart failure therapy target many of the mechanical and structural aspects of heart failure...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Thompson KA,Philip KJ,Barbagelata A,Schwarz ER

更新日期：2010-06-01 00:00:00

abstract：:Approximately 40% of heart attack survivors remain at increased risk of recurrent cardiovascular events, despite the current treatment options showing that atherothrombosis is not exclusively a disorder of lipoprotein aggregation in the arterial wall. Clinical and experimental data suggest that inflammation plays an i...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Kottoor SJ,Arora RR

更新日期：2018-11-01 00:00:00

abstract：BACKGROUND:Myocardial infarction causes the acidification of the cellular environment and the resultant acidosis maybe arrhythmogenic. The effect of acidosis on the action of antiarrhythmic drugs, an important issue in the antiarrhythmic drug therapy after myocardial infarction, remains to be studied. METHODS:To evalu...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Lin C,Ke X,Cvetanovic I,Ranade V,Somberg J

更新日期：2005-03-01 00:00:00

abstract：BACKGROUND/AIM:In addition to its cholesterol-lowering effect, atorvastatin (ATV) has been thought to have multiple cardiovascular benefits, including anti-inflammatory and anti-apoptotic properties. The present study was undertaken to determine whether ATV pretreatment could attenuate myocardial apoptosis and inflamma...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Wang JY,Chen H,Su X,Zhou Y,Li L

更新日期：2017-03-01 00:00:00

abstract：:Data obtained in both preclinical models and humans have revealed that the favorable cardiac consequences of ischemic conditioning extend beyond a direct effect on the cardiomyocyte. In the current review, we summarize our as-yet limited understanding of the complex relationships between ischemic conditioning, platele...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Przyklenk K,Whittaker P

更新日期：2017-09-01 00:00:00

abstract：BACKGROUND:epidemiologic studies indicate that elevated heart rate (HR) is an independent risk factor for mortality and morbidity in patients (pts) with chronic heart failure (CHF). Clinical trials with β-blockers suggest that HR reduction is an important mechanism of their benefit in pts with stable CHF. Pharmacologic...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Sarullo FM,Fazio G,Puccio D,Fasullo S,Paterna S,Novo S,Di Pasquale P

更新日期：2010-12-01 00:00:00

abstract：:Imipramine, an antidepressant drug, can cause potentially lethal cardiotoxic side effects including hypotension, ventricular tachycardia, and decreased cardiac output. This study investigated the mechanism responsible for imipramine-induced cardiac depression in rats. The left ventricular developed pressure (LVDP), ve...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Lee MY,Kim SJ,Kim JS,Kang HS

更新日期：2010-09-01 00:00:00

abstract：BACKGROUND:Although a gradual increase in heart rate (HR) during dobutamine stress testing (DST) is desired, few data exists regarding whether this is similarly achieved in patients of widely varying body mass index (BMI). Whether difference in BMI contributes to variation in the hemodynamic and symptomatic response to...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Kittipovanonth M,Bernheim AM,Scott CG,Barnes ME,Shub C,Pellikka PA

更新日期：2011-06-01 00:00:00

abstract：OBJECTIVE:To investigate the effect of a pharmacist care program on cardiovascular risks in type 2 diabetic patients. METHODS:A 9-month, prospective, randomized, controlled study was conducted in a public hospital in Hong Kong. Patients in the intervention group had regular drug-counseling sessions with pharmacists in...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Chan CW,Siu SC,Wong CK,Lee VW

更新日期：2012-03-01 00:00:00

abstract：BACKGROUND:Human embryonic stem cell-derived cardiomyocytes (hESC-CMs) were recently shown to be capable of electromechanical integration following direct injection into intact or recently injured guinea pig hearts, and hESC-CM transplantation in recently injured hearts correlated with improvements in contractile funct...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Shiba Y,Filice D,Fernandes S,Minami E,Dupras SK,Biber BV,Trinh P,Hirota Y,Gold JD,Viswanathan M,Laflamme MA

更新日期：2014-07-01 00:00:00

abstract：:Effects of therapy with the potassium-channel opener and vasodilator nicorandil were studied in reperfused infarction of hypertrophied hearts by using magnetic resonance imaging (MRI), hemodynamic measurements, and histochemical staining. Aortic banding was performed on 22 Sprague-Dawley rats to induce left ventricula...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Schalla S,Higgins CB,Chujo M,Saeed M

更新日期：2004-09-01 00:00:00

abstract：:BACKGROUND: The tendency for the electrophysiologic effect of class III antiarrhythmic agents (action potential prolongation) to be diminished at faster heart rates represents a major drawback of this class of drug and is usually referred to as "reverse use dependence." A novel class III agent, MS-551, has recently be...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Nakaya Y,Martin DK,Campbell TJ

更新日期：1997-01-01 00:00:00

abstract：BACKGROUND:Insulin resistance (IR) is a well-known risk factor for cardiovascular complications. This study aimed to investigate the effect of a dietary model of IR in mice on cardiac remodeling, cardiac β-arrestin2 signaling, and the protective effects of carvedilol as a β-arrestin-biased agonist. METHODS AND RESULTS...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Ibrahim WS,Ibrahim IAAE,Mahmoud MF,Mahmoud AAA

更新日期：2020-07-01 00:00:00

abstract：:Oxidative stress has been postulated to contribute to the onset and development of heart failure (HF). The efficacy of antioxidant therapy in HF, however, remains controversial. This study evaluates the effect of the antioxidant N-acetylcysteine (NAC, 1 g/kg per day) on cardiovascular function in 2- and 6-month-old Bi...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Crespo MJ,Cruz N,Altieri PI,Escobales N

更新日期：2011-06-01 00:00:00

abstract：:Phosphodiesterase inhibitors as inodilators in heart failure are associated with promotion of arrhythmias. Calcium sensitizers have been proposed for the treatment of severe decompensated heart failure. The effect of levosimendan, a calcium sensitizer, and milrinone, a phosphodiesterase inhibitor, on ventricular arrhy...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Papp JG,Pollesello P,Varró AF,Végh AS

更新日期：2006-06-01 00:00:00

abstract：BACKGROUND:Patients with coronary artery disease (CAD) should be treated with statins to attain very low cholesterol levels, in order to reduce cardiovascular adverse events. More than 70% of these patients do not reach the appropriate cholesterol goal despite moderate statin doses. However, it is not known whether the...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Pesaro AE,Serrano CV Jr,Katz M,Marti L,Fernandes JL,Parra PR,Campos AH

更新日期：2013-09-01 00:00:00